SCHEMBL4488799

SCHEMBL4488799

Cc1ccccc1NC(=O)c1cccnc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.59
MAPT P10636 2/20 0.59
HPGD P15428 3/20 0.59
ALDH1A1 P00352 3/20 0.59
HTT P42858 2/20 0.59
KDM4E B2RXH2 2/20 0.59
LMNA P02545 1/20 0.59
MAPK1 P28482 1/20 0.59
KDM4C Q9H3R0 1/20 0.55
KMT2A Q03164 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KDR P35968 1/20 0.53
POLB P06746 1/20 0.51
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
MEN1 O00255 1/20 0.50
NAPRT Q6XQN6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4498897 0.85 LMNA (0.53) HSD17B10MAPTALDH1A1KDM4ELMNA
SCHEMBL1425856 0.83 NAPRT (0.47) HSD17B10MAPTALDH1A1KDM4ELMNA
SCHEMBL4480002 0.82 CYP1A2 (0.64) HPGDHTTKMT2ACYP1A2CYP2C19
SCHEMBL24338016 0.82 MAPT (0.59) HSD17B10MAPTHPGDALDH1A1HTT
SCHEMBL21870545 0.80 KMT2A (0.63) HSD17B10MAPTHPGDALDH1A1HTT
SCHEMBL22819946 0.80 HPGD (0.68) HSD17B10MAPTHPGDALDH1A1HTT
SCHEMBL985301 0.79 L3MBTL1 (0.52) MAPTALDH1A1HTTKDM4EKMT2A
SCHEMBL30114717 0.79 HSD17B10 (0.59) HSD17B10MAPTHPGDALDH1A1HTT
SCHEMBL3690385 0.79 HPGD (0.77) HSD17B10MAPTHPGDALDH1A1HTT
SCHEMBL10816922 0.79 MAPT (0.54) HSD17B10MAPTHPGDALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937682-B1 MET KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
EP-1937682-B1 MET KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
US-7547782-B2 Met kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-16 US disclosed
WO-2007041379-A1 MET KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-12 WO disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed
US-20070078140-A1 MET kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078140-A1 MET kinase inhibitors MET, ABL1, ERBB2 HSD17B10 2762/4885MAPT 3276/4885HPGD 4066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.